Combinations of Respiratory Chain Inhibitors Have Enhanced Bactericidal Activity against Mycobacterium tuberculosis
Authors:
Open Access
- 1 January 2018
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 62 (1) , e01677-17
Abstract
As an obligate aerobe, Mycobacterium tuberculosis uses its electron transport chain (ETC) to produce energy via oxidative phosphorylation. This pathway has recently garnered a lot of attention and is a target for several new antimycobacterials. We tested the respiratory adaptation of M. tuberculosis to phenoxyalkylbenzimidazoles (PABs), compounds proposed to target QcrB, a component of the cytochrome bc 1 complex. We show that M. tuberculosis is able to reroute its ETC to provide temporary resistance to PABs. However, combination treatment of PAB with agents targeting other components of the electron transport chain overcomes this respiratory flexibility. PAB in combination with clofazimine resulted in synergistic killing of M. tuberculosis under both replicating and nonreplicating conditions. PABs in combination with bedaquiline demonstrated antagonism at early time points, particularly under nonreplicating conditions. However, this antagonistic effect disappeared within 3 weeks, when PAB-BDQ combinations became highly bactericidal; in some cases, they were better than either drug alone. This study highlights the potential for combination treatment targeting the ETC and supports the development of PABs as part of a novel drug regimen against M. tuberculosis .Keywords
Funding Information
- HHS | NIH | National Institute of Allergy and Infectious Diseases (R21AI107626)
This publication has 30 references indexed in Scilit:
- Oxidative Phosphorylation as a Target Space for Tuberculosis: Success, Caution, and Future DirectionsMicrobiology Spectrum, 2017
- Targeting Energy Metabolism in Mycobacterium tuberculosis , a New Paradigm in Antimycobacterial Drug DiscoverymBio, 2017
- Arrival of Imidazo[2,1-b]thiazole-5-carboxamides: Potent Anti-tuberculosis Agents That Target QcrBACS Infectious Diseases, 2016
- Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in Mycobacterium tuberculosis Infected C3HeB/FeJ MiceACS Infectious Diseases, 2016
- Bactericidal mode of action of bedaquilineJournal of Antimicrobial Chemotherapy, 2015
- Respiratory Flexibility in Response to Inhibition of Cytochrome c Oxidase in Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 2014
- A Dual Read-Out Assay to Evaluate the Potency of Compounds Active against Mycobacterium tuberculosisPLOS ONE, 2013
- Identification of Novel Imidazo[1,2-a]pyridine Inhibitors Targeting M. tuberculosis QcrBPLOS ONE, 2012
- Reduction of Clofazimine by Mycobacterial Type 2 NADH:Quinone OxidoreductaseJournal of Biological Chemistry, 2011
- Susceptibility testing: accurate and reproducible minimum inhibitory concentration (MIC) and non-inhibitory concentration (NIC) valuesJournal of Applied Microbiology, 2000